The new clinic will offer stem cell therapies, AI-guided health management, and combine Eastern and Western medical approaches, along with developing new immunotherapies and iPSCs.
Both countries have made similar announcements this year to favor more humane, and human-relevant methods for testing therapies, but the UK seems to lay out more specific plans and timelines.
The collaboration aims to streamline iPSC manufacturing by combining automation with standardized reagents for reproducible, scalable cell therapy processes.
Axol Bioscience’s updated iPSC library will hopefully provide researchers with diverse patient-derived cell lines and tools for advanced ophthalmology studies.
